ONC

SEC source: 0001662982-26-000006 · wk-form4_1792098516.xml · derivative · entry 11

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 403,364

Underlying: Ordinary Shares · 403,351 shares

Expires 2026-11-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F11 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F12 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on July 13, 2017, and the remaining in 36 successive equal monthly installments, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events.

SEC source: 0001662982-26-000006 · wk-form4_1792098516.xml · nonDerivative · entry 10

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.01 to $353.325, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001662982-26-000006 · wk-form4_1792098516.xml · nonDerivative · entry 9

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,260

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.99 to $352.95, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001662982-26-000006 · wk-form4_1792098516.xml · nonDerivative · entry 8

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,818

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.98 to $351.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001662982-26-000006 · wk-form4_1792098516.xml · nonDerivative · entry 7

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,499

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $349.98 to $350.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001662982-26-000006 · wk-form4_1792098516.xml · nonDerivative · entry 6

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,860

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $348.98 to $349.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001662982-26-000006 · wk-form4_1792098516.xml · nonDerivative · entry 5

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,027

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

SEC source: 0001980648-26-000027 · wk-form4_1790974392.xml · nonDerivative · entry 2

Lee Chan Henry · CIK 0001980648 · SVP, General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F2 · security: Each American Depositary Share represents 13 Ordinary Shares.

F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026.

SEC source: 0001662982-26-000004 · wk-form4_1790802681.xml · derivative · entry 16

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 806,715

Underlying: Ordinary Shares · 403,364 shares

Expires 2026-11-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F15 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F16 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on July 13, 2017, and the remaining in 36 successive equal monthly installments, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events.

SEC source: 0001662982-26-000004 · wk-form4_1790802681.xml · nonDerivative · entry 15

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.

F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $367.13 to $367.25, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001662982-26-000004 · wk-form4_1790802681.xml · nonDerivative · entry 14

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 738

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.

F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $366.13 to $367.12, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001662982-26-000004 · wk-form4_1790802681.xml · nonDerivative · entry 13

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,263

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.

F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $365.13 to $366.12, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001662982-26-000004 · wk-form4_1790802681.xml · nonDerivative · entry 12

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,310

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $363.67 to $364.62, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001662982-26-000004 · wk-form4_1790802681.xml · nonDerivative · entry 11

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,729

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $362.67 to $363.59, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001662982-26-000004 · wk-form4_1790802681.xml · nonDerivative · entry 10

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,228

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $361.66 to $362.65, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001662982-26-000004 · wk-form4_1790802681.xml · nonDerivative · entry 9

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,467

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $360.65 to $361.64, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001662982-26-000004 · wk-form4_1790802681.xml · nonDerivative · entry 8

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,708

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.

SEC source: 0001662982-26-000004 · wk-form4_1790802681.xml · nonDerivative · entry 7

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,748

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.11 to $359.01, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001662982-26-000004 · wk-form4_1790802681.xml · nonDerivative · entry 6

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,868

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.94 to $357.07, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001662982-26-000004 · wk-form4_1790802681.xml · nonDerivative · entry 5

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,028

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

SEC source: 0001193125-26-393103 · ownership.xml · derivative · entry 10

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: American Depositary Shares · 30,768 shares

Expires 2026-12-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F17 · derivative.exercise_date: The Share Options vested in 3 equal annual installments on April 19, 2018, April 19, 2019 and April 19, 2020.

F1 · ownership.nature: American Depositary Shares ("ADS") of BeOne Medicines Ltd. (the "Issuer") received upon exercise of 15,384 non-qualified share options to purchase ADS or Ordinary Shares ("Share Options") that were issued to each of Ranjeev Krishana and Michael Goller, full-time employees of Baker Bros. Advisors LP (the "Adviser") for their prior service as directors of the Issuer. Ranjeev Krishana and Michael Goller, pursuant to the policies of the Adviser, do not have any right to the pecuniary interest in the Share Options issued for their prior service on the board of directors of the Issuer (the "Board") or the ADS or Ordinary Shares received upon exercise of such Share Options.

F2 · ownership.nature: Each of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons owns an indirect proportionate pecuniary interest in the ADS received upon exercise of the Share Options issued in connection with Ranjeev Krishana and Michael Goller's prior service on the Board less the exercise cost of those Share Options.

F4 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his current service on the Board and Ranjeev Krishana and Michael Goller do not have the right to any of the Issuer's securities issued as compensation for their past service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities.

F6 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F7 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F9 · ownership.nature: Felix J. Baker serves on the Board as a representative of the Funds and their affiliates and control persons.

F11 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in securities reported in column 5 of Table I and in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F18 · ownership.nature: The ADS reported represent a total of 30,768 ADS received upon exercise of 15,384 Share Options issued to each of Ranjeev Krishana and Michael Goller. This amount is reported for each of the Funds as each has an indirect proportionate pecuniary interest in such securities.

SEC source: 0001193125-26-393103 · ownership.xml · derivative · entry 9

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: American Depositary Shares · 30,768 shares

Expires 2026-12-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F17 · derivative.exercise_date: The Share Options vested in 3 equal annual installments on April 19, 2018, April 19, 2019 and April 19, 2020.

F1 · ownership.nature: American Depositary Shares ("ADS") of BeOne Medicines Ltd. (the "Issuer") received upon exercise of 15,384 non-qualified share options to purchase ADS or Ordinary Shares ("Share Options") that were issued to each of Ranjeev Krishana and Michael Goller, full-time employees of Baker Bros. Advisors LP (the "Adviser") for their prior service as directors of the Issuer. Ranjeev Krishana and Michael Goller, pursuant to the policies of the Adviser, do not have any right to the pecuniary interest in the Share Options issued for their prior service on the board of directors of the Issuer (the "Board") or the ADS or Ordinary Shares received upon exercise of such Share Options.

F2 · ownership.nature: Each of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons owns an indirect proportionate pecuniary interest in the ADS received upon exercise of the Share Options issued in connection with Ranjeev Krishana and Michael Goller's prior service on the Board less the exercise cost of those Share Options.

F3 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in securities reported in column 5 of Table I and in column 9 of Table II directly held by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F4 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his current service on the Board and Ranjeev Krishana and Michael Goller do not have the right to any of the Issuer's securities issued as compensation for their past service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities.

F6 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F7 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F9 · ownership.nature: Felix J. Baker serves on the Board as a representative of the Funds and their affiliates and control persons.

F18 · ownership.nature: The ADS reported represent a total of 30,768 ADS received upon exercise of 15,384 Share Options issued to each of Ranjeev Krishana and Michael Goller. This amount is reported for each of the Funds as each has an indirect proportionate pecuniary interest in such securities.

SEC source: 0001193125-26-393103 · ownership.xml · nonDerivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 8,099,179

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F14 · balance_after: Each ADS represents 13 Ordinary Shares.

F1 · ownership.nature: American Depositary Shares ("ADS") of BeOne Medicines Ltd. (the "Issuer") received upon exercise of 15,384 non-qualified share options to purchase ADS or Ordinary Shares ("Share Options") that were issued to each of Ranjeev Krishana and Michael Goller, full-time employees of Baker Bros. Advisors LP (the "Adviser") for their prior service as directors of the Issuer. Ranjeev Krishana and Michael Goller, pursuant to the policies of the Adviser, do not have any right to the pecuniary interest in the Share Options issued for their prior service on the board of directors of the Issuer (the "Board") or the ADS or Ordinary Shares received upon exercise of such Share Options.

F2 · ownership.nature: Each of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons owns an indirect proportionate pecuniary interest in the ADS received upon exercise of the Share Options issued in connection with Ranjeev Krishana and Michael Goller's prior service on the Board less the exercise cost of those Share Options.

F4 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his current service on the Board and Ranjeev Krishana and Michael Goller do not have the right to any of the Issuer's securities issued as compensation for their past service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities.

F5 · ownership.nature: The Funds each own an indirect proportionate pecuniary interest in the Ordinary Shares or ADS received upon vesting of restricted share units (each an "RSU"), Share Options, and Ordinary Shares or ADS received upon the exercise of Share Options, in each case that were received as a result of Felix J. Baker's current or Ranjeev Krishana's and Michael Goller's past service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Ordinary Shares or ADS received upon vesting of RSUs, Share Options, and Ordinary Shares or ADS received upon the exercise of Share Options (i.e., no direct pecuniary interest).

F6 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F7 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F8 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Ordinary Shares or ADS received as a result of the exercise of Share Options or vesting of RSUs.

F9 · ownership.nature: Felix J. Baker serves on the Board as a representative of the Funds and their affiliates and control persons.

F11 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in securities reported in column 5 of Table I and in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F18 · ownership.nature: The ADS reported represent a total of 30,768 ADS received upon exercise of 15,384 Share Options issued to each of Ranjeev Krishana and Michael Goller. This amount is reported for each of the Funds as each has an indirect proportionate pecuniary interest in such securities.

SEC source: 0001193125-26-393103 · ownership.xml · nonDerivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 761,410

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F14 · balance_after: Each ADS represents 13 Ordinary Shares.

F1 · ownership.nature: American Depositary Shares ("ADS") of BeOne Medicines Ltd. (the "Issuer") received upon exercise of 15,384 non-qualified share options to purchase ADS or Ordinary Shares ("Share Options") that were issued to each of Ranjeev Krishana and Michael Goller, full-time employees of Baker Bros. Advisors LP (the "Adviser") for their prior service as directors of the Issuer. Ranjeev Krishana and Michael Goller, pursuant to the policies of the Adviser, do not have any right to the pecuniary interest in the Share Options issued for their prior service on the board of directors of the Issuer (the "Board") or the ADS or Ordinary Shares received upon exercise of such Share Options.

F2 · ownership.nature: Each of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons owns an indirect proportionate pecuniary interest in the ADS received upon exercise of the Share Options issued in connection with Ranjeev Krishana and Michael Goller's prior service on the Board less the exercise cost of those Share Options.

F3 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in securities reported in column 5 of Table I and in column 9 of Table II directly held by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F4 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his current service on the Board and Ranjeev Krishana and Michael Goller do not have the right to any of the Issuer's securities issued as compensation for their past service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities.

F5 · ownership.nature: The Funds each own an indirect proportionate pecuniary interest in the Ordinary Shares or ADS received upon vesting of restricted share units (each an "RSU"), Share Options, and Ordinary Shares or ADS received upon the exercise of Share Options, in each case that were received as a result of Felix J. Baker's current or Ranjeev Krishana's and Michael Goller's past service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Ordinary Shares or ADS received upon vesting of RSUs, Share Options, and Ordinary Shares or ADS received upon the exercise of Share Options (i.e., no direct pecuniary interest).

F6 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F7 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F8 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Ordinary Shares or ADS received as a result of the exercise of Share Options or vesting of RSUs.

F9 · ownership.nature: Felix J. Baker serves on the Board as a representative of the Funds and their affiliates and control persons.

F18 · ownership.nature: The ADS reported represent a total of 30,768 ADS received upon exercise of 15,384 Share Options issued to each of Ranjeev Krishana and Michael Goller. This amount is reported for each of the Funds as each has an indirect proportionate pecuniary interest in such securities.

SEC source: 0001662982-26-000002 · wk-form4_1789073392.xml · derivative · entry 14

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,210,079

Underlying: Ordinary Shares · 403,351 shares

Expires 2026-11-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F14 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F15 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on July 13, 2017, and the remaining in 36 successive equal monthly installments, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events.

SEC source: 0001662982-26-000002 · wk-form4_1789073392.xml · nonDerivative · entry 13

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.

F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.82 to $351.74, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001662982-26-000002 · wk-form4_1789073392.xml · nonDerivative · entry 12

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,278

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.

F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $349.81 to $350.80, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001662982-26-000002 · wk-form4_1789073392.xml · nonDerivative · entry 11

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,847

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $348.80 to $349.74, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001662982-26-000002 · wk-form4_1789073392.xml · nonDerivative · entry 10

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,535

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $348.07 to $348.79, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001662982-26-000002 · wk-form4_1789073392.xml · nonDerivative · entry 9

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,027

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

SEC source: 0001662982-26-000002 · wk-form4_1789073392.xml · nonDerivative · entry 8

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $347.80 to $348.07, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001662982-26-000002 · wk-form4_1789073392.xml · nonDerivative · entry 7

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,721

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $346.79 to $347.78, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001662982-26-000002 · wk-form4_1789073392.xml · nonDerivative · entry 6

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,238

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $345.71 to $346.70, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001662982-26-000002 · wk-form4_1789073392.xml · nonDerivative · entry 5

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,079

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $344.71 to $345.66, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001675628-26-000003 · wk-form4_1788470233.xml · nonDerivative · entry 2

Ball Titus B. · CIK 0001675628 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of August 31, 2023, subject to continued service.

SEC source: 0001739452-26-000011 · wk-form4_1787865149.xml · nonDerivative · entry 4

Wu Xiaobin · CIK 0001739452 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025.

SEC source: 0001042047-26-000019 · wk-form4_1786571605.xml · nonDerivative · entry 30

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F6 · security: Each American Depositary Share represents 13 Ordinary Shares.

F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026.

F29 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.95 to $359.68, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001042047-26-000019 · wk-form4_1786571605.xml · nonDerivative · entry 29

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,102

F6 · security: Each American Depositary Share represents 13 Ordinary Shares.

F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026.

F28 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.95 to $358.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001042047-26-000019 · wk-form4_1786571605.xml · nonDerivative · entry 28

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,001

F6 · security: Each American Depositary Share represents 13 Ordinary Shares.

F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026.

F27 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.95 to $357.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001042047-26-000019 · wk-form4_1786571605.xml · nonDerivative · entry 27

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,397

F6 · security: Each American Depositary Share represents 13 Ordinary Shares.

F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026.

F26 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.92 to $356.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001042047-26-000019 · wk-form4_1786571605.xml · nonDerivative · entry 26

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,912

F6 · security: Each American Depositary Share represents 13 Ordinary Shares.

F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026.

F25 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.35 to $355.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001042047-26-000019 · wk-form4_1786571605.xml · nonDerivative · entry 25

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,892

F6 · security: Each American Depositary Share represents 13 Ordinary Shares.

F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026.

SEC source: 0001042047-26-000019 · wk-form4_1786571605.xml · nonDerivative · entry 24

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,896

F6 · security: Each American Depositary Share represents 13 Ordinary Shares.

F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026.

F24 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $366.00 to $366.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001042047-26-000019 · wk-form4_1786571605.xml · nonDerivative · entry 23

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,096

F6 · security: Each American Depositary Share represents 13 Ordinary Shares.

F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026.

F23 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $365.00 to $365.90, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001042047-26-000019 · wk-form4_1786571605.xml · nonDerivative · entry 22

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,272

F6 · security: Each American Depositary Share represents 13 Ordinary Shares.

F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026.

F22 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $363.95 to $364.90, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001042047-26-000019 · wk-form4_1786571605.xml · nonDerivative · entry 21

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,483

F6 · security: Each American Depositary Share represents 13 Ordinary Shares.

F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026.

F21 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $362.95 to $363.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001042047-26-000019 · wk-form4_1786571605.xml · nonDerivative · entry 20

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 77,886

F6 · security: Each American Depositary Share represents 13 Ordinary Shares.

F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026.

F20 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $361.94 to $362.74, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001042047-26-000019 · wk-form4_1786571605.xml · nonDerivative · entry 19

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 89,454

F6 · security: Each American Depositary Share represents 13 Ordinary Shares.

F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026.

F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $360.92 to $361.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001042047-26-000019 · wk-form4_1786571605.xml · nonDerivative · entry 18

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,023

F6 · security: Each American Depositary Share represents 13 Ordinary Shares.

F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026.

F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.92 to $360.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001042047-26-000019 · wk-form4_1786571605.xml · nonDerivative · entry 17

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 112,104

F6 · security: Each American Depositary Share represents 13 Ordinary Shares.

F7 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026.

F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.90 to $359.89, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.